Evidence supporting the use of: Aniracetam
For the health condition: Senility
Synopsis
Source of validity: Scientific
Rating (out of 5): 2
Aniracetam is a synthetic nootropic compound in the racetam family, primarily investigated for its potential cognitive-enhancing and neuroprotective effects. Its use to support or treat senility, particularly age-related cognitive decline or mild cognitive impairment, is based on limited scientific evidence, mostly from animal models and a small number of human clinical studies.
Preclinical research indicates that Aniracetam may modulate AMPA receptors and enhance cholinergic neurotransmission, which are both implicated in learning and memory processes. Animal studies have shown that Aniracetam can improve memory and learning in models of cognitive impairment. In terms of human data, a few small-scale clinical trials and open-label studies have reported improvements in cognitive function, memory, and mood in elderly patients with cognitive deficits, including those with mild dementia or senile symptoms. However, these studies often suffer from methodological limitations such as small sample sizes, short durations, and lack of rigorous controls.
Systematic reviews note that while Aniracetam and other racetams are used in some countries for age-related cognitive decline, the overall quality and quantity of evidence remain low. Regulatory agencies in the US and most of Europe have not approved Aniracetam for the treatment of senility or dementia, citing insufficient proof of efficacy and safety. In summary, while there is some scientific evidence supporting Aniracetam's use for senility, it is limited and not robust, warranting a modest evidence rating.
Other health conditions supported by Aniracetam
Alzheimer's DiseaseAnxiety
Apathy
Concentration (poor)
Confusion
Dementia
Depression
Memory and Brain Function
Senility
Thinking (cloudy)